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Background: 5-aminosalicylates (5-ASA) are widely used in inflammatory bowel dis-
ease (IBD), but emerging evidence suggests that they may be safely withdrawn in sig-
nificant subsets of patients. This is important to address: 5-ASA therapy accounts for 
up to 25% of total healthcare costs in ulcerative colitis (UC), while almost a third of 
patients with Crohn's disease (CD) receive long-term 5-ASA despite no clear evidence 
of benefit. Further, rationalising medication burden may improve overall adherence 
and outcome.
Aims: To summarise the rationale for 5-ASA withdrawal, review the current evidence 
in both UC and CD and consider the data surrounding colorectal cancer (CRC) preven-
tion, guiding an evidence-based withdrawal strategy.
Methods: PubMed was searched to identify relevant studies. Only papers pub-
lished in English were reviewed, with priority given to randomised clinical trials and 
meta-analyses.
Results: For patients with UC, consideration of 5-ASA withdrawal should be made on a 
case-by-case basis, but it appears safest for those in deep remission without any of the 
following risk factors: younger age (<40 years), remission for less than 2 years, a his-
tory of multiple flares, extensive disease. 5-ASA withdrawal should also be considered 
in patients with UC escalated to biologic therapy who have achieved remission and in 
all patients with CD. Although 5-ASA therapy may have chemopreventive benefits for 
CRC, the cost-benefit ratio appears significant, and this indication is not justified by 
evidence in those who have achieved remission and are continuing therapy with other 
agents, or in those in sustained remission without a history of extensive disease.
Conclusions: Although the majority of patients with IBD receive 5-ASA during their 
disease course, safe withdrawal appears possible in many, with important implications 
for both health economics and patient experience. A number of unanswered ques-
tions, however, remain.
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1  | INTRODUCTION
5-aminosalicylates (5-ASA) are the mainstay of treatment for 
mild-to-moderate ulcerative colitis (UC) and are widely prescribed.1,2 
Indeed, 88%-97% of patients receive 5-ASA therapy within a year of 
first diagnosis, with 60%-87% continuing at 10 years.3 However, de-
spite the increasing therapeutic armamentarium available, it is appar-
ent from clinical trial data that clinicians persist with 5-ASA therapy 
even when it has demonstrably failed and treatment escalation is un-
dertaken. In the ACT1 and 2 studies of infliximab in moderate-to-se-
vere UC, approximately 70% of patients received concurrent 5-ASA,4 
with the PURSUIT studies of golimumab a decade later showing pre-
scribing habits remained unchanged.5 Furthermore, over half of pa-
tients with Crohn's disease (CD) receive 5-ASA during their disease 
course, with up to 30% continuing long term, despite no convincing 
evidence of benefit and both European and US guidelines advising 
against their use.6-10
At a time of increasing pressure on healthcare budgets world-
wide, recent guidelines have emphasised the importance of address-
ing low-value healthcare.11,12 The true cost of 5-ASA therapy is often 
underappreciated by clinicians, with a study in the United Kingdom 
suggesting it accounted for up to 25% of total healthcare costs in 
UC, with an average annual maintenance prescription estimated to 
be £740/€850.13,14 There is little evidence that 5-ASA expenditure 
is reducing, although a very recent study has suggested that the in-
creasing use of biologic therapy has reduced the relative contribution 
of 5-ASA to total healthcare costs in UC.15 However, it is notable that 
the cost differential with some biologics has now begun to narrow 
significantly with the advent of anti-tumour necrosis factor (TNF) 
biosimilars.
While rightly considered to be a safe and well-tolerated therapeu-
tic class, 5-ASA have been associated with rare but serious idiosyn-
cratic adverse effects including pancreatitis, although a recent study 
has cast doubt on the association with nephrotoxicity,16 while around 
3% of patients report a paradoxical worsening of diarrhoea.17 Of 
more significant concern is the observation that use of 5-ASA in CD 
may delay the introduction of effective therapy, potentially impairing 
clinical outcomes. The negative impact of polypharmacy must also be 
considered, with non-adherence linked to higher daily pill burden.18 
Indeed, the additional burden of an inconvenient and more complex 
medication regimen has been linked to poorer outcomes in both UC 
and a variety of other conditions, with real-world compliance as low 
as 50%.19 Furthermore, topical 5-ASA therapy is frequently poorly 
tolerated by patients, and adherence is significantly worse than oral 
therapy.20
There is thus a clear need to consider the issue of withdrawal of 
5-ASA therapy in IBD, with emerging evidence suggesting it may be 
safely stopped in significant subsets of patients. In this review, we 
comprehensively discuss the data surrounding 5-ASA withdrawal 
in both UC and CD, including the role of 5-ASA in colorectal can-
cer (CRC) chemoprevention. We review the advice from recent drug 
withdrawal guidelines and propose a withdrawal strategy before con-
cluding with future perspectives.
1.1 | Search strategy
An electronic search of Pubmed was conducted to identify relevant 
manuscripts from their inception until February 2020. The search 
combined the MeSH terms “inflammatory bowel disease”, “Ulcerative 
Colitis” and “Crohn's Disease” with the subheadings “5-ASA with-
drawal”, “5-ASA de-escalation”, “risk of relapse”, “cost saving” and 
“colorectal cancer”. We also reviewed bibliographies of the included 
studies to identify additional important data. Recent guidelines and 
topical reviews were also assessed. Only papers published in English 
were reviewed, with priority given to randomised clinical trials (RCT) 
and meta-analyses.
2  | 5-ASA WITHDR AWAL IN UC
2.1 | Withdrawal of topical 5-ASA monotherapy in 
distal colitis
Six randomised clinical trials have evaluated topical 5-ASA with-
drawal in patients with distal UC (Table 1).21-26 All RCTs assessed me-
salazine (mesalamine)-based treatment, but the frequency and mode 
of administration varied between the studies. The longest follow-up 
period was 2 years post-withdrawal.23 All 6 RCTs reported higher re-
lapse rates in the placebo group compared to the 5-ASA treatment 
group. Relapse rates in the placebo group ranged from 52% to 85% at 
12 months up to 91% at 24 months, whereas relapse rates in patients 
who continued 5-ASA ranged from 20% to 48% at 12 months up to 
55% at 24 months. In summary, stopping topical therapy in distal UC 
is associated with significantly higher rates of disease relapse. No 
studies were identified that assessed dose de-escalation, although 
reduction in frequency of administration is commonly used in clini-
cal practice once remission has been achieved. Furthermore, 1 g of 
mesalazine once daily appears to be the optimal dose for induction of 
remission, suggesting no benefit to more frequent dosing strategies 
in maintenance of remission.27
2.2 | Withdrawal of oral 5-ASA monotherapy
In total, five RCTs were identified that assessed withdrawal of oral 
5-ASA therapy in UC (Table 2).28-32 A total of 515 patients were 
analysed during 6-12 months of follow-up. Although the 5-ASA 
preparation and frequency varied, with sulfasalazine, olsalazine and 
mesalazine all assessed, most RCTs28-30,32 found a higher rate of re-
lapse in patients who stopped oral 5-ASA compared to those who 
continued therapy. Relapse rates in the placebo group ranged from 
29% to 60.3% at 6 months and 26% to 49% at 12 months, whereas 
relapse rates in patients who continued 5-ASA ranged from 12.1% to 
41.2% at 6 months and from 18% to 23% at 12 months. Only a single 
RCT found no significant difference in relapse rate but relapse was 
defined solely with clinical symptoms leading to risk of bias.31 Results 
from retrospective studies are in agreement with the overall RCT 
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findings, with relapse rates higher than 50% in patients who stopped 
5-ASA reported.33 Importantly, Ardizzone et al compared 12-month 
relapse rates with duration of remission before therapy withdrawal.28 
Patients who had been in remission for more than 2 years before 
withdrawal of 5-ASA did not have a significantly higher relapse rate 
than those who continued (26% vs 18%, P = 0.35). In comparison, 
patients who had been in remission for 1-2 years before withdrawal 
of 5-ASA did have a significantly higher relapse rate than those who 
continued (49% vs 23%, P = 0.035). The authors concluded that con-
tinuation of 5-ASA treatment is necessary for patients who have 
been in remission for less than 2 years. In summary, withdrawal of 
oral 5-ASA when used as monotherapy is associated with a higher 
relapse rate. However, the majority of studies included patients who 
had been in remission for less than 12 months before withdrawal, and 
thus further studies assessing the safety of withdrawal in patients in 
long-term remission are warranted.
2.3 | Dose de-escalation of 5-ASA therapy
Although the risk of relapse on withdrawal of 5-ASA monotherapy 
appears high, an alternative approach is dose reduction, which may 
still yield important cost savings and reduce pill burden. European 
Crohn's and Colitis Organisation (ECCO) guidelines on the manage-
ment of UC suggest that 2 g daily of oral 5-ASA is effective in main-
taining remission, while for distal disease topical treatment with 3 g/
week in divided doses may be sufficient.1 A retrospective national 
database study of 4452 patients found no significant difference in 
risk of flares between patients treated with low- (2.2-2.8 g/day) vs 
high-dose (4.4-4.8 g/day) mesalazine, during a median of follow-up 
of 6 years.34 However, patients with low adherence had a lower risk 
of relapse with high-dose 5-ASA (hazard ratio [HR] 0.28, P = 0.003).34 
As expected, one RCT found that a dose of just 1.2 g/day oral mesala-
zine was less effective than 2.4 g/day in maintaining remission, par-
ticularly in those patients with a history of more frequent relapses.35 
A further RCT found that 4.8 g/day oral mesalazine was superior to 
2.4 g/day in maintaining remission in patients under the age of 40 
and/or with extensive disease.36 In summary, it appears safe to dose 
de-escalate in selected patients, but those younger than 40 years, or 
who have poor adherence or extensive colitis may require continua-
tion of high-dose 5-ASA.
2.4 | Withdrawal of topical and/ or oral 5-ASA when 
used in combination
Three studies have evaluated topical 5-ASA withdrawal in patients 
treated with concomitant oral therapy. D’Albasio et al randomised 
patients either to receive combined therapy with oral 5-ASA 4.6 g/
day and 5-ASA enemas 4 g twice weekly or oral 5-ASA with placebo 
enemas over 12 months. Relapse rates were higher in patients where 
topical 5-ASA therapy was withdrawn in comparison to those where 
both oral and topical 5-ASA therapy was continued (23/36 patients 
69% vs 13/33 39%, P = 0.036).37 Similarly, Yokoyama et al randomised 
patients either to receive oral 5-ASA (3 g/day) with 5-ASA enema 1g 
twice weekly or oral 5-ASA alone. The enemas were only administered 
at weekends, with the hypothesis that they would be better tolerated 
by patients who worked or attended school. Relapse rates were again 
higher in patients where topical 5-ASA therapy was withdrawn (10/13 
patients 76.9% vs 2/11 18.2%).38 Piodi et al compared combined ther-
apy with oral 5-ASA (1.6 g/day) and 5-ASA enemas (2 g twice weekly) 
with oral 5-ASA monotherapy. Patients on combined therapy had 
lower mean relapse rate (1.59 vs 2.76, P = 0.034) and higher probability 
of not having a first relapse during the observation period (0.59 vs 0.29, 
P = 0.001).39 In summary, continuation of topical therapy is associated 
with higher rates of remission in patients with concomitant oral 5-ASA 
therapy, although the study by Yokoyama et al suggested that it may 
be possible to de-escalate the frequency of topical therapy, given the 
promising results from a weekend enema alone.38 Importantly, all stud-
ies included patients who had been in remission for only a month prior 
to de-escalation, and thus the outcome in patients in long-term remis-
sion requires further investigation.
2.5 | Withdrawal of 5-ASA in patients treated with 
immunomodulators
Two studies have evaluated the outcome of oral 5-ASA withdrawal 
in patients treated with concomitant immunomodulators. Mantzaris 
et al randomised 70 steroid-dependent patients with UC to receive 
azathioprine (AZA) monotherapy (34/70) or in combination with ol-
salazine (36/70) for 2 years with no difference in relapse rates re-
ported (26.2% vs 25%, P = NS). However, treatment compliance was 
significantly better for the AZA monotherapy group (97% vs 85%, 
P < 0.001).40 In a retrospective study of patients with IBD in clinical 
remission for a minimum of 6 months that included 82 patients with 
UC, no difference in relapse rate was found between patients with 
UC receiving either AZA monotherapy or combination AZA and oral 
5-ASA therapy (0.19 relapse per year of follow-up vs 0.21/year of fol-
low-up, P = 0.69), during a 4.3-year follow-up period.41 Importantly, 
both studies only assessed clinical relapse, with no biochemical or 
endoscopic evaluation included, and thus the overall level of evidence 
must be considered weak.40 Therefore, further prospective studies 
are warranted to clarify if 5-ASA therapy can be safely withdrawn 
in patients on AZA. Interestingly, it has been suggested that 5-ASA 
therapy may potentiate thiopurine efficacy, with studies demon-
strating that mesalazine increases levels of the active thiopurine 
metabolite 6-thioguanine, although the mechanism for this remains 
unclear.42,43
2.6 | Withdrawal of 5-ASA in patients treated with 
biologic therapy or tofacitinib
No RCTs have yet evaluated the outcome of 5-ASA withdrawal in pa-
tients treated with biologic therapy. However, a recent retrospective 
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cohort study provides important data.44 A total of 3589 patients with 
moderate-to-severe UC from two national population-based data-
bases (USA and Denmark) were included to compare adverse clinical 
events in patients who discontinued oral 5-ASA within 90 days of initi-
ation of anti-TNF therapy with those who continued 5-ASA. Stopping 
5-ASA did not increase the risk of adverse clinical events, including 
corticosteroid use (2.7% vs 4.3%, P = 0.10), hospitalisation (5.2% vs 
6.2%, P = 0.70) and surgery (6.7% vs 7.7%, P = 0.46). Overall, stop-
ping 5-ASA did not increase the risk of adverse clinical events in either 
the US cohort (aHR 1.04, 95% CI 0.88-1.23, P = 0.67) or the Danish 
cohort (adjusted hazard ratio [aHR] 1.09, 95% CI 0.80-1.49, P = 0.6). 
Results were similar in sensitivity analyses assessing concomitant im-
munomodulator therapy and duration of 5-ASA treatment.
Separately, a post hoc analysis of clinical trials assessed the out-
come of concomitant 5-ASA in patients escalated to anti-TNF ther-
apy, although the issue of 5-ASA withdrawal was not specifically 
addressed.45 An individual participant data analysis of 2183 patients 
pooled from 5 clinical trials of infliximab and golimumab in moder-
ate-to-severe UC were undertaken. Maintenance of 5-ASA oral 
therapy was not associated with increased odds of clinical remission 
(adjusted odds ratio [aOR] 0.67, P = 0.06), clinical response (aOR 0.89, 
P = 0.58), biochemical response (aOR 0.94, P = 0.79) or mucosal heal-
ing (aOR 1.12, P = 0.48). However, the impact on two important long-
term outcomes, surgery and risk of CRC, was not assessed.
A further recent retrospective cohort study has assessed concom-
itant 5-ASA therapy in patients treated with the anti-integrin therapy 
vedolizumab.46 There was no difference in steroid-free clinical remis-
sion (56.8% vs 66%, P = 0.36) or endoscopic remission (42.5% vs 53.1%, 
P = 0.32) in patients treated with or without aminosalicylates, in a 12-
month period of follow-up. These data are further supported by results 
from a post hoc analysis of the GEMINI long-term safety study, with no 
difference found in survival probabilities for vedolizumab treatment 
persistence at 54 months, between patients who initiated vedolizumab 
with or without concomitant medications, including 5-ASA.47
No prospective studies or RCTs have evaluated the outcome of 
5-ASA withdrawal in patients treated with the Janus kinase (JAK) in-
hibitor tofacitinib. Indirect evidence from subgroup analysis of RCTs 
suggests concomitant 5-ASA at trial entry does not affect likelihood 
of maintaining clinical remission after escalation to tofacitinib or an-
ti-TNF therapy (relative risk [RR] 0.92, 95% CI 0.78-1.09).48
In summary, concomitant 5-ASA therapy in patients escalated 
either to anti-TNF or vedolizumab does not appear to improve UC-
related outcomes and withdrawal may therefore be considered. 
However, data from randomised controlled trials, where withdrawal 
of 5-ASA therapy is directly compared to continuation in patients es-
calated to advanced therapy, are required to confirm these findings.
2.7 | Predictive factors for relapse on withdrawal of 
5-ASA in UC
Few studies have identified clear predictive factors for relapse after 
5-ASA withdrawal. As discussed above, it appears that patients 
younger than 40 years and/or with more extensive disease are at 
higher risk of relapse on dose de-escalation.34,35 Both of these factors 
have been associated with a more active disease course, which itself 
is very likely to predict a higher risk of relapse on 5-ASA withdrawal.
Increasing interest has focussed on whether the attainment of deep 
remission, defined as clinical, biochemical and endoscopic remission, 
is associated with reduced risk of relapse. However, to date only his-
tological grade has been clearly associated with risk of relapse in pa-
tients with UC.49 In a prospective study of 179 patients, the relative 
risk of clinical relapse was 3.5 (95% CI 1.9-6.4, P < 0.0001) in patients 
where baseline Geboes grade was >3.1 following multivariate analysis. 
In contrast, baseline Mayo endoscopy score (MES) was associated with 
risk of relapse on univariate but not multivariate analysis. However, a 
retrospective study has suggested that remission is more likely to be 
maintained following 5-ASA dose de-escalation if MES is 0.50
Recently it has been shown that faecal calprotectin (FC) may be 
used as a non-invasive surrogate measure of histological remission. A 
review of 12 studies, involving 1168 patients, found that FC positively 
correlated with histologic disease activity in all studies. However, no 
single cut-off value could be obtained to accurately predict histologic 
remission, with values ranging from 40.5 to 250 µg/g, as the cut-off 
level varied between studies and test used, and according to the defi-
nition of histological remission.51 Although no study has specifically 
assessed the use of FC to guide 5-ASA withdrawal in UC, two pro-
spective studies have suggested that patients in clinical remission on 
oral 5-ASA with FC levels >200 and 300 µg/g, respectively, were at 
higher risk of relapse.52,53
2.8 | Monitoring and treatment of relapse
It is clear that patients and clinicians alike may underestimate the rel-
evance of mild symptoms,54 and thus it is essential that patients are 
objectively monitored for evidence of disease relapse if 5-ASA is with-
drawn. FC has recently emerged as a potentially useful objective predic-
tor of early relapse before clinical recurrence. One prospective study 
has suggested that higher FC predicts short-term risk of relapse in pa-
tients in deep remission following anti-TNF withdrawal, with FC levels 
elevated up to 6 months before evidence of endoscopic activity.55
No studies have yet directly addressed the efficacy of re-treat-
ment with 5-ASA in the event of relapse. Two studies have, however, 
suggested that dose escalation of 5-ASA in patients in clinical remis-
sion with elevated FC lowers relapse rate, suggesting that FC moni-
toring might allow early reintroduction or dose escalation of 5-ASA 
before clinical recurrence.42,43
3  | 5-ASA WITHDR AWAL IN CD
3.1 | Withdrawal of 5-ASA monotherapy
Despite ongoing widespread use of 5-ASA monotherapy in CD, most 
commonly in elderly patients or those with mild disease,8,9 there are 
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little data on outcomes following withdrawal. It is, however, clear 
that 5-ASA are ineffective in maintaining remission, with a Cochrane 
meta-analysis of 2014 patients from 11 studies reporting no differ-
ence in relapse rate at 1 year follow-up between patients treated with 
5-ASA and placebo (53% (526/998) vs 54% (544/1016), RR 0.98, 95% 
CI 0.91-1.07, P = 0.70).56 The overall data, although only of moder-
ate quality, were considered sufficient for the authors to recommend 
that additional randomised trials may not be justified. However, a ret-
rospective Danish study of 537 patients with CD treated with first-
line mesalazine monotherapy had previously raised the concept of 
5-ASA dependency.57 This phenomenon, defined as clinical relapse 
within 1 year of stopping mesalazine with a regain of response after 
restarting mesalazine, was observed in 23%. These results should, 
however, be interpreted with caution as they are at risk of significant 
bias, including a failure to consider factors known to influence disease 
course such as smoking status. Furthermore, the apparent sympto-
matic benefit may simply be explained by a placebo effect, which is 
well documented in CD.58
Separate research has focussed on the potential role of 5-ASA to 
prevent relapse following surgery for CD. A Cochrane meta-analysis 
of 730 patients from 5 RCTs reported a lower rate of clinical relapse 
in patients treated with 5-ASA vs placebo (36% (131/361) vs 43% 
(160/369) (RR 0.83, 95% CI 0.72-0.96)), during a follow-up that ranged 
from 48 to 72 weeks.59 No conclusion could, however, be made based 
on endoscopic or radiological evidence of relapse due to insufficient 
data. Again, without clear objective evidence of benefit, these results 
should therefore be interpreted with caution, and once again the ap-
parent symptomatic benefit may be explained by a placebo effect.
3.2 | Withdrawal of 5-ASA in patients treated with 
immunomodulators
A retrospective study by Campbell et al that included 104 patients 
with CD on azathioprine found no difference in relapse rate between 
those on combination therapy and those on azathioprine alone (mean 
relapse rate 0.27/year vs 0.30/year, P = ns).41 No studies have re-
ported withdrawal of 5-ASA therapy from patients on combination 
therapy with methotrexate.
3.3 | Withdrawal of 5-ASA in patients treated with 
biologic therapy
A recent large retrospective database analysis of 3178 patients with 
CD, comprising independent cohorts from the United States (2960 
patients) and Denmark (218 patients), explored the effects of discon-
tinuing mesalazine therapy when initiating anti-TNF. No increased 
risk of adverse clinical events (corticosteroid use, hospitalisation or 
surgery) on withdrawal of mesalazine was found following multivari-
able Cox regression modelling in either the US cohort (aHR 0.89, 95% 
CI 0.77-1.03, P = 0.13) or the Danish cohort (aHR 1.13, 95% CI 0.68-
1.87, P = 0.63).44 Furthermore, and in agreement with the study by 
Campbell et al, the concurrent use of immunomodulators had no ap-
parent effect on the risk of adverse outcomes following mesalazine 
withdrawal.41 No studies have yet assessed 5-ASA withdrawal in pa-
tients treated with vedolizumab or the anti-IL12/23 biologic usteki-
numab in CD, but there is no reason to suspect an increased risk of 
adverse events.
4  | THE ROLE OF 5-ASA IN CRC 
PRE VENTION—A KE Y CONSIDER ATION?
The development of CRC in patients with inflammatory bowel disease 
is a significant concern for both clinicians and patients, with a meta-
analysis of 116 studies from across the world reporting an incidence 
of 0.3% per year in UC,60 and a separate meta-analysis suggesting a 
comparable risk in Crohn's colitis.61 A very recent population-based 
cohort study from Scandinavia has suggested that the risk of CRC 
for patients with UC has decreased over the last five decades, with 
an overall HR of 1.66 (95% CI 1.57-1.76) compared to the general 
population.61 In a separate population-based cohort study, the same 
authors reported a HR of 1.74 (95% CI 1.54-1.96) for patents with CD 
compared to the general population.63
The potential role of 5-ASA in CRC prevention is consequently 
of great interest. It is clear that CRC risk depends on inflammation 
dependent factors, namely duration, extent and severity of colonic 
disease and inflammation independent factors, predominantly family 
history and presence of primary sclerosing cholangitis (PSC).64 The 
first benefit of 5-ASA appears to relate to control of colonic inflam-
mation, and therefore as expected is not specific to 5-ASA. A recent 
systematic review and meta-analysis of 27 studies involving 95 937 
patients with IBD demonstrated that thiopurine use was associated 
with a reduced risk of both high-grade dysplasia and CRC, particu-
larly among those with a longer disease duration,65 although the 
risk reduction appeared limited to those with UC in a separate me-
ta-analysis.66 The second potential benefit relates to the postulated 
direct chemopreventive effects of 5-ASA, with studies suggesting a 
range of relevant biological mechanisms including cell checkpoint ac-
tivation,67 improvement of DNA replication fidelity,68 scavenging of 
reactive oxygen and nitrogen species69 and interference with Wnt/
beta-catenin signalling.70 A recent observational study evaluated 
transcript levels of carcinogenesis-associated known 5-ASA target 
genes in colonic mucosa from patients with UC receiving long-term 
5-ASA therapy. Significant suppression of the expression of a num-
ber of carcinogenesis-associated genes was reported in serial colonic 
biopsy specimens, with some transcript level changes independent 
of parameters of disease severity.71 These apparent direct chemo-
preventive effects are noteworthy and may provide a rationale for 
long-term 5-ASA use.
A meta-analysis of 31 observational studies including 2137 cases 
of colorectal neoplasia, of which 76% were cancer, found that 5-ASA at 
therapeutic dose was associated with a significant reduction in neoplasia 
in UC (RR 0.54, 95% CI 0.38-0.64) but not CD (RR 0.76, 95% CI 0.43-
1.33), with no benefit seen with sulfasalazine.72 It is notable, however, 
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that not all studies have reported a protective effect, including a popula-
tion-based study from Canada,73 and indeed the overall effect appears 
consistently weaker in population-based studies.72 The cost-benefit ratio 
of 5-ASA in chemoprevention has been estimated at 153 × annual cost 
of therapy per CRC prevented, which would be equivalent to around 
£110 000/€130 000.64 This estimate may, however, significantly over-
estimate the cost benefit particularly if, as seems almost certain, the 
protective effect of 5-ASA is partly due to improved disease control. 
This represents a considerable expenditure, which might conceivably be 
spent more effectively on other strategies to prevent CRC including im-
proved disease control and endoscopic surveillance.
British Society of Gastroenterology (BSG) guidelines state that 
patients with UC or IBD-U (IBD unclassified) with left-sided or more 
extensive disease should be advised to take at least 2 g mesalazine 
daily to reduce risk of CRC.2 ECCO guidance is that the lifelong che-
moprevention with 5-ASA is justified in all patients with UC, except 
for those with isolated proctitis.74 While the most recent guidelines 
from the American Gastroenterological Association advise that 
5-ASA may be withdrawn in all who have achieved remission with im-
munomodulator, biologic agents or tofacitinib, this recommendation 
did not factor in the potential chemopreventive benefit of 5-ASA.48 
However, the AGA guidelines do note that sustained remission ap-
pears protective regardless of the type of therapy used.
5  | STATE OF ART
5.1 | Current recommendations for the withdrawal 
of 5-ASA therapy in IBD
In 2018, ECCO published guidance on treatment withdrawal in IBD, includ-
ing 5-ASA. In general, it was suggested that 5-ASA treatments should not 
be discontinued in patients with UC, even during remission, considering 
their benefits for both disease control and prevention of CRC. However, 
the importance of individualising any withdrawal decision is emphasised, 
and it was suggested that treatment withdrawal might be considered in 
patients with limited disease extent, a history of remission for several 
years, a history of a single disease flare only and no previous requirement 
for systemic corticosteroid therapy.75 However, this guidance predates 
the recent publications suggesting no benefit to concomitant 5-ASA in 
patients escalated to anti-TNF or vediolizumab.44,46 As noted above, in 
the recent AGA guidelines on management of moderate-to-severe UC, it 
has been suggested that 5-ASA therapy may be stopped in patients who 
have achieved remission with biologic agents and/or immunomodulators, 
or tofacitinib.48 Neither European nor US guidelines recommend the use 
of 5-ASA therapy in CD.6,7
5.2 | A proposed withdrawal strategy
While we accept that some of the data described in this review are de-
rived from studies that did not directly address the question of 5-ASA 
withdrawal, and there are still important gaps in our knowledge, we 
believe there is now sufficient evidence to guide decision making on 
5-ASA withdrawal in significant subsets of patients. We propose that 
5-ASA withdrawal should be considered in all patients with CD, but 
only following careful discussion with the patient, as they may be re-
luctant to consider this. A pro-active strategy of objective monitoring 
for evidence of relapse, including use of FC, may provide reassurance 
for both clinician and patient following withdrawal. For patients with 
PSC and IBD, who are at highest risk of CRC, it may be appropriate 
to continue 5-ASA for the additional chemopreventive benefits, al-
though a low level of evidence supports this.
For patients with UC, consideration of 5-ASA withdrawal should 
be made on a case by case basis in collaboration with the patient, with 
decision making based on the presence or absence of key risk fac-
tors. For patients on high-dose 5-ASA dose de-escalation rather than 
complete withdrawal may still yield important benefits. A potential 
algorithm is outlined in Figure 1.
As with CD, patients with UC may develop a psychological de-
pendency upon 5-ASA, with a perception that it continues to provide 
substantial benefit from previously distressing symptoms, and careful 
discussion may therefore be required. Although recent data suggest 
no benefit to continuing 5-ASA in patients escalated to biologic ther-
apy, these studies were underpowered to assess the potential che-
mopreventive benefits of 5-ASA.46,76 While we await further studies 
to help address the relative contributions of different UC medications 
to CRC prevention, it may be safest to continue 5-ASA until remission 
has been achieved with biologic therapy, although patients can be 
de-escalated from high-dose 5-ASA. As it currently remains difficult 
to accurately predict who may relapse, patients should be reassured 
that they will be closely monitored following de-escalation, allowing 
early detection of disease recurrence. The cost and potential incon-
venience of this monitoring may, however, be significant and should 
be considered when weighing up 5-ASA withdrawal, although a FC 
test costs considerably less than 1 month of oral 5-ASA therapy.13 
The current life circumstances should also be considered; for exam-
ple, one might decide not to de-escalate prior to a period of travelling 
where monitoring might be difficult, or prior to events such as univer-
sity examinations where a flare may be more challenging.
6  | FUTURE PERSPECTIVES
Despite the convincing evidence to date and clear advice from na-
tional guidelines, clinicians continue to prescribe 5-ASA in CD. The 
ongoing STATIC study (Stopping Aminosalicylate Therapy in Inactive 
Crohn's Disease, NCT03261206), where patients with CD in clinical 
remission are randomised either to continue or stop 5-ASA therapy, 
with the primary outcome CD-related complications at 24 months 
will provide important prospective data with the hope it will finally 
change practice. Furthermore, increasing awareness of the need to 
target low-value healthcare, and the future emergence of effective 
and safe, well-tolerated treatments appropriate for mild colonic CD, 
or indeed the acceptance that no treatment may be an acceptable 
approach, may also change prescribing habits.
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The ongoing use of 5-ASA therapy in UC once patients are esca-
lated to the latest advanced therapies including tofacitinib also awaits 
clarification, although it seems likely that there will be no clear added 
benefit, as already reported with anti-TNF and vedolizumab.46,76
With an ever increasing array of treatment options, personal-
isation of approach to IBD therapy is essential and remains a crit-
ical unmet research need. Indeed, no biomarkers yet exist either 
to predict response to 5-ASA therapy or reliably identify when 
it may be safely withdrawn. The potential cost savings of any 
clinically useful biomarkers to guide use of 5-ASA therapy would 
be significant and we suggest that further evaluation of the role 
of FC should be a particular priority. Furthermore, the use of 
telemedicine systems, which allow closer monitoring of disease 
activity, might allow earlier detection of relapse following 5-ASA 
withdrawal, allowing rapid reintroduction and providing reassur-
ance for both patients and their clinicians (Table 3).77,78
In conclusion, although the majority of patients with IBD re-
ceive 5-ASA during their disease course, a number of unanswered 
questions still surround how it should be most effectively used and 
when it should be withdrawn. Despite this, it is increasingly clear that 
5-ASA withdrawal may be safe and indeed appropriate in significant 
F I G U R E  1   A strategy for 5-ASA de-escalation in ulcerative colitis. For patients with primary sclerosing cholangitis, it may be appropriate 




• Mayo endoscopy score
Biochemical remission?
• Faecal calprotectin
Escalated to biological therapy?
Consider de-escalation
Consider de-escalation




• History of multiple flares









• Is patient willing to de-escalate?
• Does patient know risk of relapse?
• Life circumstances
Lower risk patient Higher risk patient (≥1 risk factor)
TA B L E  3   Unanswered questions surrounding 5-ASA withdrawal
Ulcerative colitis
Safety of 5-ASA monotherapy withdrawal following longer-term 
remission in higher-risk groups
Safety of 5-ASA withdrawal when on concomitant 
immunomodulatory
Safety of 5-ASA withdrawal when escalated to newer advanced 
therapies
Predictive factors and biomarkers for relapse on 5-ASA 
withdrawal
Crohn's disease
Safety of 5-ASA withdrawal in apparent 5-ASA dependency and 
following surgical resection
82  |     CHAPMAN et Al.
subsets of patients, with important implications for both health eco-
nomics and patient experience.
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